Target type: biologicalprocess
Any process that increases the frequency, rate or extent of chromatin binding. Chromatin binding is the selective interaction with chromatin, the network of fibers of DNA, protein, and sometimes RNA, that make up the chromosomes of the eukaryotic nucleus during interphase. [GOC:bf, PMID:20404130]
Positive regulation of chromatin binding is a complex process that governs the accessibility of DNA to regulatory factors. It involves a dynamic interplay of various molecular players, including transcription factors, chromatin remodelers, and histone modifiers, working in concert to modulate the structure and function of chromatin.
**Chromatin Structure:**
Chromatin, the compact form of DNA in the nucleus, is organized into nucleosomes, which consist of DNA wrapped around histone proteins. The arrangement of nucleosomes and the modifications on histone tails contribute to the accessibility of DNA to regulatory factors.
**Positive Regulation:**
Positive regulation of chromatin binding refers to the processes that increase the accessibility of DNA to regulatory factors, enabling gene expression. This can occur through:
* **Recruitment of Transcription Factors:** Transcription factors bind to specific DNA sequences, initiating gene expression. Their recruitment can be facilitated by various mechanisms, including protein-protein interactions and post-translational modifications.
* **Chromatin Remodeling:** ATP-dependent chromatin remodelers utilize the energy from ATP hydrolysis to reposition nucleosomes, creating more accessible DNA regions. These remodelers can slide nucleosomes along DNA, remove nucleosomes, or exchange histone variants.
* **Histone Modifications:** Covalent modifications, such as acetylation, methylation, and phosphorylation, occur on histone tails, influencing chromatin structure. These modifications can recruit specific proteins, leading to changes in chromatin accessibility.
**Specific Examples:**
* **Acetylation:** Acetylation of lysine residues on histone tails typically correlates with relaxed chromatin structure and increased gene expression. Acetyltransferases (HATs) add acetyl groups, while histone deacetylases (HDACs) remove them.
* **Methylation:** Methylation of lysine residues on histone tails can have varied effects on chromatin accessibility, depending on the specific lysine residue and the degree of methylation.
* **Phosphorylation:** Phosphorylation of serine and threonine residues on histone tails is often associated with gene activation, affecting chromatin structure and recruitment of regulatory factors.
**Overall, positive regulation of chromatin binding involves a coordinated interplay of these factors, creating a dynamic and flexible environment for gene regulation. This process is essential for cellular processes such as development, differentiation, and responses to environmental cues.'
"
Protein | Definition | Taxonomy |
---|---|---|
Protein mono-ADP-ribosyltransferase PARP9 | A protein mono-ADP-ribosyltransferase PARP9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8IXQ6] | Homo sapiens (human) |
Mediator of RNA polymerase II transcription subunit 25 | A mediator of RNA polymerase II transcription subunit 25 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q71SY5] | Homo sapiens (human) |
Lysine-specific demethylase 4D | A lysine-specific demethylase 4D that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q6B0I6] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
2,4-pyridinedicarboxylic acid | lutidinic acid : A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 4. | pyridinedicarboxylic acid | |
5-carboxy-8-hydroxyquinoline | 5-carboxy-8-hydroxyquinoline: a JmjC histone demethylase inhibitor; structure in first source | quinolines | |
norstictic acid | norstictic acid: from Xanthoparmelia chlorochroa; structure in first source | ||
rucaparib | AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source | azepinoindole; caprolactams; organofluorine compound; secondary amino compound | antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor |